TRIUMPH-1 Explained: What to Expect From Retatrutide’s Pivotal Phase 3 Obesity Readout
If you’ve been following retatrutide for months — refreshing news pages, tracking Eli Lilly’s pipeline updates, and waiting for the obesity numbers everyone keeps talking about — you’re not alone. The trial that will actually decide retatrutide’s case for FDA approval as a weight-management drug is called TRIUMPH-1, and as of May 2026 it has not yet reported. Here’s what is known, what to watch for, and what the readout will and won’t tell us.
TRIUMPH-1 is the pivotal Phase 3 trial of retatrutide in adults with obesity or overweight who do not have type 2 diabetes. It enrolled approximately 2,300 participants, runs for 80 weeks of placebo-controlled treatment, and is designed as the apples-to-apples analogue of the trials that supported approval for tirzepatide (SURMOUNT-1) and semaglutide (STEP-1). Eli Lilly has publicly guided to a Q2 to Q3 2026 readout.
When TRIUMPH-1 reports, it will — together with TRIUMPH-2 in type 2 diabetes — anchor Lilly’s New Drug Application for retatrutide. Until that data is published, every weight-loss number you see for retatrutide as a future obesity drug ultimately traces back to its Phase 2 results or to TRIUMPH-4 in adults with knee osteoarthritis. TRIUMPH-1 is the trial that closes that gap.
What TRIUMPH-1 Actually Is
TRIUMPH-1 is a randomized, double-blind, placebo-controlled Phase 3 trial of retatrutide in adults with obesity or overweight who do not have type 2 diabetes. It is registered on ClinicalTrials.gov as NCT05929066 and is the largest single trial in Eli Lilly’s TRIUMPH Phase 3 program, which includes eight parallel pivotal studies across more than 5,800 participants in total.
The trial enrolled approximately 2,300 participants. About 80% have a body mass index (BMI) of 35 or higher, with the remaining 20% in the BMI 27 to under 35 range with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. Female enrollment was capped at roughly 70% of the trial population.
The placebo-controlled treatment period lasts 80 weeks. After the placebo-controlled period, participants who were on placebo cross over to retatrutide for an additional 24 weeks of open-label treatment, which gives Lilly the cleanest possible comparison between drug and placebo at the primary endpoint without leaving placebo participants without options afterward.
Why TRIUMPH-1 Is the Trial That Matters Most
Every approved obesity drug in the modern GLP-1 era has been carried by a single pivotal weight-loss trial in adults with obesity who do not have diabetes. For semaglutide it was STEP-1. For tirzepatide it was SURMOUNT-1. TRIUMPH-1 is built to occupy that same slot for retatrutide.
That positioning matters for two reasons. First, regulators and payers compare new obesity drugs against the existing benchmark trials, so TRIUMPH-1’s design — duration, population, primary endpoint — has to be close enough to those benchmarks for the comparison to hold. Second, the obesity-only population is the largest commercial indication, so TRIUMPH-1 is the trial Lilly is most likely to point to in promotional materials, payer negotiations, and clinical-guideline submissions once approval comes.
If TRIUMPH-1 reproduces or exceeds the weight-loss signal already seen in earlier retatrutide data, the New Drug Application timeline effectively locks in. If TRIUMPH-1 underperforms or surfaces a new safety signal, the entire commercial case has to be reconsidered. Either way, this is the readout that materially changes the picture.
The Benchmarks Going In
Two prior retatrutide datasets define what TRIUMPH-1 is being measured against.
The first is the Phase 2 retatrutide trial published in *The New England Journal of Medicine* in 2023, which reported a mean 24.2% body-weight reduction at the highest dose at 48 weeks in adults with obesity. That result drew unusual attention at the time because it was the first widely cited Phase 2 obesity number to clear the 20% threshold without bariatric surgery.
The second is TRIUMPH-4, the first Phase 3 retatrutide trial to report. In December 2025, Eli Lilly announced that participants with obesity and knee osteoarthritis taking retatrutide 12 mg lost a mean 28.7% of body weight at 68 weeks. TRIUMPH-4 was a smaller and more specific population than TRIUMPH-1, but it was a successful Phase 3 readout, and it raised — rather than lowered — the bar for what TRIUMPH-1 is now expected to deliver.
These benchmarks set up a relatively narrow band of plausible outcomes for TRIUMPH-1. A weight reduction in the low to mid-twenties at 80 weeks would be consistent with the existing data. A number in the high twenties or above would meaningfully exceed expectations. A number in the mid-teens or lower would be a surprise to the downside.
What ‘Success’ Will Actually Look Like
Three things will determine whether TRIUMPH-1 is read as a clean win.
First, the placebo-adjusted weight-loss percentage at week 80. The headline number that gets reported in press releases is typically the absolute weight change in the retatrutide group, but the placebo-adjusted figure (drug minus placebo) is what regulators and clinicians weigh most heavily.
Second, the proportion of participants reaching specific weight-loss thresholds — typically 5%, 10%, 15%, 20%, and 25% body-weight loss. These categorical responder analyses translate trial data into something patients and clinicians can reason about. Drugs that move a large share of participants past 20% body-weight loss are treated differently from drugs that average a high number while leaving many participants below 10%.
Third, the safety profile across the full 80-week period. Earlier retatrutide trials have shown a typical incretin-class adverse-event profile, weighted toward nausea, diarrhea, and vomiting during dose escalation. TRIUMPH-1 is the first time the field will see a long-duration safety dataset of this size for retatrutide specifically.
What TRIUMPH-1 Will Not Answer
It is worth being explicit about the questions this trial will not resolve, because those gaps shape what comes next.
TRIUMPH-1 is placebo-controlled, not active-comparator. It will not tell us how retatrutide compares head-to-head against tirzepatide or semaglutide on any endpoint. The active-comparator data is expected to come later from other trials in the program.
It will also not tell us much about real-world use patterns: insurance coverage, adherence at scale, response in patients with conditions excluded from the trial, or what happens when people stop the drug. Those questions become answerable only after approval, real-world prescribing, and post-marketing studies.
And TRIUMPH-1 alone does not deliver a label. The U.S. label for retatrutide will reflect both TRIUMPH-1 and TRIUMPH-2 (the Phase 3 trial in adults with obesity and type 2 diabetes), as well as supportive data from TRIUMPH-4 and the broader TRANSCEND program. Approval timing and label scope are functions of the full data package, not any single trial.
How the Readout Connects to Approval Timing
Lilly has publicly indicated plans to submit a New Drug Application for retatrutide in 2026, anchored by TRIUMPH-1 and TRIUMPH-2 data. A Q2 to Q3 2026 TRIUMPH-1 readout would line up with that submission window.
Once a New Drug Application is filed, the FDA’s standard review timelines apply. Priority review and breakthrough designation can compress that timeline; standard review extends it. The path from successful TRIUMPH-1 readout to U.S. availability is therefore measured not in days but in quarters — even in the most optimistic scenario.
For the most current view of what is publicly known about retatrutide’s regulatory progress, see our retatrutide approval updates page and our overview of whether retatrutide is FDA-approved.
What to Watch For When the Press Release Drops
When TRIUMPH-1 finally reads out, three details in the announcement will tell you almost everything you need to interpret the result quickly.
Look first for the placebo-adjusted mean body-weight reduction at week 80 in the highest-dose arm. Then look for the proportion of participants reaching a 25% body-weight reduction, which has become the new informal benchmark for next-generation obesity drugs. Finally, look at the discontinuation rate due to adverse events in the highest-dose arm, which is the cleanest signal of how tolerable the drug actually is over an extended treatment period.
These three numbers — efficacy, depth of response, tolerability — are the lens through which TRIUMPH-1 will be read by clinicians, payers, and the broader scientific community. We will publish a dedicated results post here as soon as the data is released, and the TRIUMPH program research hub will be updated with the full picture.
Stay Updated
Want to be notified the moment TRIUMPH-1 reports? Join our retatrutide updates list and we’ll send a single, plain-English summary as soon as the data is released. We do not share your information.
Disclaimer
Retatrutide is an investigational medication. It is not approved by the FDA for any indication and is not commercially available. This post is educational and should not be interpreted as medical advice. For information about how our content is created and reviewed, see our editorial policy and medical review policy.
FAQ SECTION
When is TRIUMPH-1 expected to report results?
Eli Lilly has publicly guided to a Q2 to Q3 2026 readout for TRIUMPH-1. As of May 2026, no topline announcement has been made. When results are released, they will typically appear first as an Eli Lilly investor press release, followed within months by a peer-reviewed journal publication and conference presentation.
How many people are enrolled in TRIUMPH-1?
TRIUMPH-1 enrolled approximately 2,300 participants, making it the largest single trial in retatrutide’s Phase 3 program. About 80% of participants have a BMI of 35 or higher, with the remaining 20% in the BMI 27 to under 35 range and at least one weight-related comorbidity. Female enrollment was capped at roughly 70%.
Is TRIUMPH-1 a placebo-controlled trial?
Yes. TRIUMPH-1 is randomized, double-blind, and placebo-controlled. Participants and investigators do not know who is receiving retatrutide and who is receiving placebo during the 80-week treatment period. Placebo participants cross over to retatrutide for 24 weeks of open-label treatment after the primary endpoint to ensure they have access to the drug if it succeeds.
How long is the TRIUMPH-1 treatment period?
The placebo-controlled treatment period in TRIUMPH-1 is 80 weeks, which is longer than the 68-week treatment period used in tirzepatide’s SURMOUNT-1 and the 68-week period used in semaglutide’s STEP-1. The longer duration is meant to capture both the depth of weight loss and the durability of the response over a year and a half of treatment.
How does TRIUMPH-1 differ from SURMOUNT-1 and STEP-1?
TRIUMPH-1 follows the same general design template as SURMOUNT-1 (tirzepatide) and STEP-1 (semaglutide): a placebo-controlled Phase 3 trial in adults with obesity who do not have type 2 diabetes. The primary differences are duration (80 weeks versus 68 weeks), enrollment size (approximately 2,300 versus 2,539 in SURMOUNT-1 and 1,961 in STEP-1), and the drug being tested — retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors, where tirzepatide is a dual agonist (GLP-1, GIP) and semaglutide is a single agonist (GLP-1).
